FDA approves Lundbeck’s Vyepti™ (eptinezumab-jjmr) – the first and only intravenous preventive treatment for migraine

On February 21, 2020, the FDA approved eptinezumab-jjmr (VYEPTI™) for the preventive treatment of migraine in adults. This is the first intravenous (IV) treatment for migraine prevention and the latest in a new class of monoclonal antibodies used for the preventive treatment of migraine.

Eptinezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor. The drug is expected to launch commercially in April of 2020 and should be administered every three (3) months via a 30-minute IV infusion.


This is yet another very exciting development for people living with migraine.

Call The Manhattan Center for Headache & Neurology to learn more about Vyepti. Let us help you lead a pain free life!